Antiplatelet agents in the prevention of diabetic vascular complications.
Patrono
C
C
Department of Pharmacology, University of Chieti, G. D'Annunzio, School of Medicine, Italy.
Daví
G
G
D001241:Aspirin / Q000009:adverse effects / Q000627:therapeutic use*; D003920:Diabetes Mellitus / Q000097:blood*; D003925:Diabetic Angiopathies / Q000517:prevention & control*; D003928:Diabetic Nephropathies / Q000503:physiopathology / Q000517:prevention & control*; D003930:Diabetic Retinopathy / Q000503:physiopathology / Q000517:prevention & control*; D006801:Humans; D015539:Platelet Activation; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic
D010975:Platelet Aggregation Inhibitors; D001241:Aspirin